Oral sustained-release preparation of L-Dopa in the management of fluctuations in Parkinson's disease

6 months follow-up

F. Stocchi, M. Bragoni, A. Monge, D. Bravi, L. Giorgi, F. Viselli, S. Ruggieri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

10 patients suffering from Parkinson's disease were selected for this study because of their predictable fluctuations in motor performances and nocturnal akinesia. 7 patients out of these 10, were treated with a sustained release formulation of L-Dopa plus PDDI (Madopar HBS) for six months. The remaining 3 patients dropped out of the study within the initial 30 days of treatment. The clinical evaluation and the diary of the patients showed an improvement of the fluctuations, nocturnal akinesia and 'Off period dystonia'. The dosage was 60% greater on average than the corresponding dose of the standard drug. The improvement remained constant during the trial period and no side effects or complications were reported.

Original languageEnglish
Pages (from-to)29-38
Number of pages10
JournalNew Trends in Clinical Neuropharmacology
Volume3
Issue number1
Publication statusPublished - 1989

Fingerprint

Delayed-Action Preparations
Levodopa
Parkinson Disease
Dystonia
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology

Cite this

Oral sustained-release preparation of L-Dopa in the management of fluctuations in Parkinson's disease : 6 months follow-up. / Stocchi, F.; Bragoni, M.; Monge, A.; Bravi, D.; Giorgi, L.; Viselli, F.; Ruggieri, S.

In: New Trends in Clinical Neuropharmacology, Vol. 3, No. 1, 1989, p. 29-38.

Research output: Contribution to journalArticle

Stocchi, F. ; Bragoni, M. ; Monge, A. ; Bravi, D. ; Giorgi, L. ; Viselli, F. ; Ruggieri, S. / Oral sustained-release preparation of L-Dopa in the management of fluctuations in Parkinson's disease : 6 months follow-up. In: New Trends in Clinical Neuropharmacology. 1989 ; Vol. 3, No. 1. pp. 29-38.
@article{8063ea6d5e4140fe9b2ab68eeeb28f46,
title = "Oral sustained-release preparation of L-Dopa in the management of fluctuations in Parkinson's disease: 6 months follow-up",
abstract = "10 patients suffering from Parkinson's disease were selected for this study because of their predictable fluctuations in motor performances and nocturnal akinesia. 7 patients out of these 10, were treated with a sustained release formulation of L-Dopa plus PDDI (Madopar HBS) for six months. The remaining 3 patients dropped out of the study within the initial 30 days of treatment. The clinical evaluation and the diary of the patients showed an improvement of the fluctuations, nocturnal akinesia and 'Off period dystonia'. The dosage was 60{\%} greater on average than the corresponding dose of the standard drug. The improvement remained constant during the trial period and no side effects or complications were reported.",
author = "F. Stocchi and M. Bragoni and A. Monge and D. Bravi and L. Giorgi and F. Viselli and S. Ruggieri",
year = "1989",
language = "English",
volume = "3",
pages = "29--38",
journal = "New Trends in Clinical Neuropharmacology",
issn = "0393-5345",
number = "1",

}

TY - JOUR

T1 - Oral sustained-release preparation of L-Dopa in the management of fluctuations in Parkinson's disease

T2 - 6 months follow-up

AU - Stocchi, F.

AU - Bragoni, M.

AU - Monge, A.

AU - Bravi, D.

AU - Giorgi, L.

AU - Viselli, F.

AU - Ruggieri, S.

PY - 1989

Y1 - 1989

N2 - 10 patients suffering from Parkinson's disease were selected for this study because of their predictable fluctuations in motor performances and nocturnal akinesia. 7 patients out of these 10, were treated with a sustained release formulation of L-Dopa plus PDDI (Madopar HBS) for six months. The remaining 3 patients dropped out of the study within the initial 30 days of treatment. The clinical evaluation and the diary of the patients showed an improvement of the fluctuations, nocturnal akinesia and 'Off period dystonia'. The dosage was 60% greater on average than the corresponding dose of the standard drug. The improvement remained constant during the trial period and no side effects or complications were reported.

AB - 10 patients suffering from Parkinson's disease were selected for this study because of their predictable fluctuations in motor performances and nocturnal akinesia. 7 patients out of these 10, were treated with a sustained release formulation of L-Dopa plus PDDI (Madopar HBS) for six months. The remaining 3 patients dropped out of the study within the initial 30 days of treatment. The clinical evaluation and the diary of the patients showed an improvement of the fluctuations, nocturnal akinesia and 'Off period dystonia'. The dosage was 60% greater on average than the corresponding dose of the standard drug. The improvement remained constant during the trial period and no side effects or complications were reported.

UR - http://www.scopus.com/inward/record.url?scp=0024435179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024435179&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 29

EP - 38

JO - New Trends in Clinical Neuropharmacology

JF - New Trends in Clinical Neuropharmacology

SN - 0393-5345

IS - 1

ER -